🧬 Amivantamab in METex14 NSCLC – a step forward or a sign we still have work to do? 📊From CHRYSALIS (n=97): ORR overall: 32% Treatment-naïve: 50% Prior MET TKI: 19% Median PFS: 5.3 mo | OS: 15.8 mo DoR ≥6 mo in 61% of responders ⚠️ Limited post-TKI efficacy. 🧠 Bispecific +

🚨Rare cancers account for 25% of all cases, yet face trial designs built for the common. Limited accrual, scarce funding, rigid endpoints—these barriers persist. But hope lies in: 🔹 Basket & adaptive designs 🔹 Tumor-agnostic therapies 🔹 N-of-1 & AI-driven trial matching 🔹

Navigational bronchoscopy as the new standard for biopsy of lung nodules? Non-inferiority trial NEJM compared robotic bronch to transthoracic needle biopsy with similar accuracy (79% vs 74%) but bronch with lower risk of pneumothorax (3.3% vs 28.3%). nejm.org/doi/full/10.10…

Dr. Herbert Loong, MBBS, FASCO at #ASCO25 with update on SOHO-01 with sevanertinib (BAY 2927088) in #HER2 NSCLC. RR 60.5% in pts with prior treatment (no HER2 therapy), DOR 9.2m. In 1L setting, RR 59% and most ongoing. Safety notable for >80% of pts with diarrhea though.

🫁 #LungCancer Oral Abstract Session #ASCO25 Comprehensive discussion by Marcelo Corassa, MD. 🇧🇷 on efficacy, safety, and sequencing of novel therapies for HER2 and EGFR Exon 20 ins NSCLC Just like heading to McCormick place all routes / approaches will be needed while balancing

🧬 #ASCO25 | SACHI Trial Osimertinib + Savolitinib in EGFRm/METamp NSCLC (post-EGFR TKI) Oral, chemo-free combo shows promising activity: 🔹 PFS 8.2 mo in ITT population 🔹 PFS 9.9 mo post 1st/2nd-gen EGFR TKIs 🔹 PFS 6.8 mo post 3rd-gen (osimertinib) 🔹 PFS 9.6 mo in pts w/o

🧬 #ASCO25 | OptiTROP-Lung03 Sacituzumab Tirumotecan (sac-TMT) vs docetaxel in EGFRm NSCLC post-TKI 🔹 Primary endpoint (ORR): 45.1% vs 15.6% (p=0.0004) 🔹 PFS: 6.9 vs 2.8 mo (HR 0.30; p<0.0001) 🔹 OS: Not reached, but strong trend (HR 0.49; p=0.007) 🔹 Crossover: 36.4% to

🧬 #ASCO25 | HERTHENA-Lung02 Patritumab Deruxtecan (HER3-DXd) in EGFRm NSCLC post-TKI 🔹 PFS: 5.8 vs 5.4 mo (HR 0.77; p=0.011) 🔹 16.0 vs 15.9 mo (HR 0.98) — no improvement 🔹 Safety: ILD 5.2%; grade ≥3 AEs in 72.8% 🔹 Bottom line: Statistically significant ≠ clinically

🚨 Updated results from #CheckMate77T at #ASCO25 🧬 Perioperative nivolumab improved: 📌EFS 46.6 vs 16.9 mo (HR 0.61) ✔️ EFS vs PBO regardless of KRAS, KEAP1, STK11 ✔️ Lung cancer-specific survival (HR 0.60) ✔️ EFS in ctDNA clearance + pCR 📉 OS trend favored NIVO 🛡️ No new

Phase II #2SMALL trial results at #ASCO25: 💊 Lurbinectedin + atezolizumab as 2L in advanced #SCLC: ✅ ORR: 40.4% 🕑 Median PFS: 4.6 mo | OS: 10.1 mo 🧬 Activity in IO-pretreated & platinum-resistant patients 👍 Manageable safety profile, no treatment-related deaths Presented

🚨Neoadjuvant alectinib in resectable stage III ALK+ NSCLC (ALNEO, phase II): 🫁 MPR 42% (90% CI, 28–58) 🧬 pCR 12% (95% CI, 3–28) 📉Nodal downstaging in 48% 🛡️ Well-tolerated, consistent with known alectinib safety Suggests perioperative alectinib as a feasible. #ASCO25

Todo sobre el Cáncer de Pulmón: Factores de riesgo y diagnóstico temprano youtu.be/VhkdAf95ibg?si… a través de YouTube

A practical guide on managing toxicities from lorlatinib chronically now Lung Cancer Journal, developed collaboratively by patients with #ALK NSCLC ALK Positive. lungcancerjournal.info/article/S0169-…

Real world outcomes in #BRAF NSCLC reported Clinical Lung Cancer. 1L dabrafenib + trametinib RR 67%, PFS 13.1m compared to chemotherapy RR 39%, PFS 6.1m. D+T performed similarly across lines. Question remains: targeted vs immunotherapy first? I prefer targeted. clinical-lung-cancer.com/article/S1525-…

Comparison of EGFR NSCLC transformed to #SCLC vs de novo SCLC Lung Cancer Journal. OS shorter with transformed SCLC esp with high neuroendocrine marker expression. In transformed SCLC, OS with chemo-immunotherapy superior to chemo +/- TKI (15.4m vs 8.5m). lungcancerjournal.info/article/S0169-…